Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12421287

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421231

Azaindole derivatives and their use as ERK kinase inhibitors

AGV Discovery · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421236

Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

Medshine Discovery Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421280

Insulin like growth factor binding protein bioactive peptide fragments

Northwestern University · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421302

CAR-t cells and autoimmune diseases

The Regents of the University of California · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421525

Conjugates comprising AAVs and CAS9 polypeptides

The Regents of the University of California · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12419877

Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compos

Akebia Therapeutics, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414934

Combination therapies

Aardvark Therapeutics, Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414942

Compositions, methods, and systems for treating presbyopia

LENZ THERAPEUTICS OPERATIONS, INC. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12416008

Compositions and methods of use for small-molecule regulation of CRISPR-Cas9 activity usin

The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415867

Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use

The Board of Regents of the University of Oklahoma · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415995

Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferatio

Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12416006

Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use ther

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415861

Anti C-MET antibodies

CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415863

Compositions and methods for treating cancer

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415856

EGFR x CD28 multispecific antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415845

Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415854

Antibodies to TIGIT

Arcus Biosciences, Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415866

Monoclonal antibody inhibitor of Factor XIIa

Takeda Pharmaceutical Company Limited · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414981

JNK inhibitors for use in treating and preventing neurodegenerative disorders

Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415843

Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatm

The Regents of the University of California · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414983

CD200AR ligands for cancer immunotherapy

Regents of the University of Minnesota · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415782

Heterocyclic compound and use thereof

Takeda Pharmaceutical Company Limited · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12414995

Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer

Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted